A new clinical study indicates that 40 mg of UC-II, a patented type II collagen product from Benicia, CA-based InterHealth Nutraceuticals, reduces osteoarthritic pain as measured by three index scores. For this randomized, double-blind study of 52 patients, one group took 40 mg UC-II and the other a combination of glucosamine (1500 mg) and chondroitin (1200 mg). The results indicate UC-II had a significant improvement from baseline on all WOMAC, VAS, and Lequesne measurements over the glucosamine and chondroitin combination. Treatment with UC-II was found to be significantly more effective and reduced the WOMAC score by 33% compared to 14% in glucosamine plus chondroitin treated groups after 90 days. Similar results were obtained for VAS scores. The Lequesne’s functional index was used to determine the effect of different treatments on pain during daily activities. Treatment with UC-II reduced Lequesne’s functional index score by 20% compared to 6% in glucosamine plus chondroitin treated groups.